Ciarka Aleksandra, Kunc Michał, Popęda Marta, Łacko Aleksandra, Radecka Barbara, Braun Marcin, Pikiel Joanna, Litwiniuk Maria, Pogoda Katarzyna, Iżycka-Świeszewska Ewa, Zeller Anna, Niemira Magdalena, Pęksa Rafał, Biernat Wojciech, Senkus Elżbieta
Department of Pathology, Medical University of Gdańsk, Gdańsk, Poland.
Department of Oncology, Wrocław Medical University, Wrocław, Poland.
Contemp Oncol (Pozn). 2024;28(1):75-83. doi: 10.5114/wo.2024.139375. Epub 2024 May 3.
This study aimed to evaluate the impact of tumour-infiltrating lymphocytes (TILs) on the expression of immune-related genes and prognosis in single hormone receptor-positive breast cancer. Material and methods: Tumour-infiltrating lymphocytes were analysed according to the guidelines of the International TILs Working Group in a cohort of 206 patients with single hormone receptor-positive breast cancer. Of these, 44.7% were classified as ER+/PgR-/HER2-, 18.4% as ER+/PgR-/HER2+, 26.2% as ER-/PgR+/HER2-, and 10.7% as ER-/PgR+/HER2+. Moreover, in 52 samples the analysis of gene expression profiling was performed using nCounter technology.
Most cases (74.3%) showed at least 1% of stromal TILs, with a median of 4%, mean of 16.3%, and interquartile range of 0-20%. ER-/PgR+ tumours displayed significantly higher TILs density than ER+/PgR- cases (p < 0.001, Wilcoxon test), regardless of HER2 status. The abundance of TILs was positively associated with ER-/PgR+ phenotype, higher Ki-67, and higher grade, but not with age, tumour size, or regional and distant metastases at diagnosis. Additionally, in ER+/PgR- subgroup higher TILs were associated with HER2-positive status. Stromal TILs > 5% were associated with better survival in the whole group, but this effect was less prominent in ER-/PgR+ patients. We identified 50 differentially expressed genes (DEGs) between single hormone receptor-positive breast tumours with high and low TILs, including 39 up-regulated and 11 down-regulated genes in the high TILs group.
The up-regulated expression of immune-related genes was consistent also among separately analysed single hormone receptor-positive groups (ER+/PgR- and ER-/PgR+).
本研究旨在评估肿瘤浸润淋巴细胞(TILs)对单激素受体阳性乳腺癌中免疫相关基因表达及预后的影响。材料与方法:根据国际TILs工作组的指南,对206例单激素受体阳性乳腺癌患者队列中的肿瘤浸润淋巴细胞进行分析。其中,44.7%被分类为ER+/PgR-/HER2-,18.4%为ER+/PgR-/HER2+,26.2%为ER-/PgR+/HER2-,10.7%为ER-/PgR+/HER2+。此外,对52个样本使用nCounter技术进行基因表达谱分析。
大多数病例(74.3%)显示至少1%的基质TILs,中位数为4%,平均值为16.3%,四分位间距为0-20%。无论HER2状态如何,ER-/PgR+肿瘤的TILs密度均显著高于ER+/PgR-病例(p<0.001,Wilcoxon检验)。TILs的丰度与ER-/PgR+表型、较高的Ki-67和较高的分级呈正相关,但与年龄、肿瘤大小或诊断时的区域及远处转移无关。此外,在ER+/PgR-亚组中,较高的TILs与HER2阳性状态相关。基质TILs>5%与全组更好的生存率相关,但在ER-/PgR+患者中这种效应不太明显。我们在高TILs和低TILs的单激素受体阳性乳腺肿瘤之间鉴定出50个差异表达基因(DEGs),包括高TILs组中39个上调基因和11个下调基因。
在单独分析的单激素受体阳性组(ER+/PgR-和ER-/PgR+)中,免疫相关基因的上调表达也是一致的。